D.E. Shaw & Co
ORIC icon

D.E. Shaw & Co’s Oric Pharmaceuticals ORIC Stock Holding History

D.E. Shaw & Co’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$562K Buy
44,390
+28,368
+177% +$322K ﹤0.01% 3788
2025
Q4 		$131K Buy
+16,022
New +$184K ﹤0.01% 4381
2024
Q1 		– Sell
-98,433
Closed -$906K – 4623
2023
Q4 		$906K Sell
98,433
-209,046
-68% -$1.51M ﹤0.01% 3200
2023
Q3 		$1.86M Sell
307,479
-145,770
-32% -$1.19M ﹤0.01% 2631
2023
Q2 		$3.52M Sell
453,249
-125,054
-22% -$710K ﹤0.01% 2146
2023
Q1 		$3.3M Sell
578,303
-24,484
-4% -$128K ﹤0.01% 2304
2022
Q4 		$3.55M Buy
602,787
+68,899
+13% +$233K ﹤0.01% 2412
2022
Q3 		$1.71M Buy
533,888
+27,901
+6% +$112K ﹤0.01% 3137
2022
Q2 		$2.27M Buy
505,987
+261,088
+107% +$1.04M ﹤0.01% 2957
2022
Q1 		$1.31M Buy
+244,899
New +$2.21M ﹤0.01% 3689
2021
Q2 		– Sell
-9,812
Closed -$240K – 4942
2021
Q1 		$240K Buy
+9,812
New +$310K ﹤0.01% 3790

Other funds holding ORIC

NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

D.E. Shaw & Co's ORIC Position: Q1 2026 in Review

D.E. Shaw & Co increased its Oric Pharmaceuticals (ORIC) stake by 177% in Q1 2026, buying an estimated $322K and bringing the position to 44,390 shares worth $562K. The position accounts for ﹤0.01% of the portfolio, ranked #3788.

D.E. Shaw & Co first reported a position in ORIC in Q1 2021 and has held it in 11 quarters since. The position peaked at $3.55M in Q4 2022. 182 funds tracked by Wall St. Rank hold ORIC as of Q1 2026.

  • D.E. Shaw & Co held 44,390 shares of Oric Pharmaceuticals worth $562K as of Q1 2026.
  • D.E. Shaw & Co bought 28,368 Oric Pharmaceuticals shares in Q1 2026, an estimated $322K.
  • Oric Pharmaceuticals made up ﹤0.01% of D.E. Shaw & Co's portfolio in Q1 2026, its #3788 holding.
  • D.E. Shaw & Co first reported a position in Oric Pharmaceuticals in Q1 2021 and has held it in 11 quarters since.
  • D.E. Shaw & Co's Oric Pharmaceuticals position peaked at $3.55M in Q4 2022.
  • 182 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q1 2026.

Based on D.E. Shaw & Co's 13F filing for Q1 2026, filed 15 May 2026.